• Featured Product
  • KD/KO Validated

BCRP,ABCG2 Polyclonal antibody

BCRP,ABCG2 Polyclonal Antibody for IHC, WB,ELISA

Host / Isotype

Rabbit / IgG


human, mouse and More (1)





Cat no : 27286-1-AP


ABC15, ABCG2, ABCP, BCRP,ABCG2, BMDP, CD338, CDw338, EST157481, MRX, MXR, MXR1

Tested Applications

Positive WB detected inHepG2 cells, HEK-293 cells, MCF-7 cells
Positive IHC detected inhuman liver cancer tissue, human breast cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

Western Blot (WB)WB : 1:500-1:2000
Immunohistochemistry (IHC)IHC : 1:50-1:500
Sample-dependent, check data in validation data gallery

Product Information

The immunogen of 27286-1-AP is BCRP,ABCG2 Fusion Protein expressed in E. coli.

Tested Reactivity human, mouse
Cited Reactivityhuman, mouse, rat
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen BCRP,ABCG2 fusion protein Ag25911
Full Name ATP-binding cassette, sub-family G (WHITE), member 2
Calculated molecular weight 70 kDa
Observed molecular weight 68-72 kDa
GenBank accession numberBC021281
Gene symbol ABCG2
Gene ID (NCBI) 9429
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

BCRP (breast cancer resistance protein) confers a broad spectrum of drug resistance and the expression of BCRP is enhanced in several cancer cell models. It has ATPase activity and belongs to a family of multiple drug resistant proteins. Data also indicated that BCRP might be an early marker for some stem cells.


Product Specific Protocols
WB protocol for BCRP,ABCG2 antibody 27286-1-APDownload protocol
IHC protocol for BCRP,ABCG2 antibody 27286-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols



Eur J Pharmacol

Dual actions of norathyriol as a new candidate hypouricaemic agent: uricosuric effects and xanthine oxidase inhibition.

Authors - Hua Lin

Cell Death Dis

UBE2O promotes the proliferation, EMT and stemness properties of breast cancer cells through the UBE2O/AMPKα2/mTORC1-MYC positive feedback loop.

Authors - Xu Liu

Cancers (Basel)

Preclinical Evaluation of the Novel Small-Molecule MSI-N1014 for Treating Drug-Resistant Colon Cancer via the LGR5/β-catenin/miR-142-3p Network and Reducing Cancer-Associated Fibroblast Transformation.

Authors - Vijesh Kumar Yadav

Cell Death Dis

1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells.

Authors - Zhirong Jia

J Exp Clin Cancer Res

Pharmacological targeting PTK6 inhibits the JAK2/STAT3 sustained stemness and reverses chemoresistance of colorectal cancer.

Authors - Chaoqun Liu

Biol Pharm Bull

Olsalazine Sodium Increases Renal Urate Excretion by Modulating Urate Transporters in Hyperuricemic Animals.

Authors - Yanfen Niu